Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer

PURCHASE, N.Y. , May 01, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), today announced the appointment of John Doyle to the role of chief financial officer. Mr. Doyle has substantial experience leading and managing financial operations at development- and commercial-stage public life sciences companies through financings, mergers, acquisitions and licensing agreements.

“John has significant experience raising capital in challenging markets and leading companies through the evolution to commercialization. We look forward to leveraging his skills, his relationships on Wall Street, and his strategic insights as we move forward together as a company,” said , Cognition’s president and CEO.

Mr. Doyle was most recently chief financial officer of 4D Pharma plc, and previously was SVP and chief financial officer of Chiasma Inc. During his tenure at Chiasma Inc, the company began reporting commercial sales and ultimately completed a merger with Amryt Pharma. Earlier, he served in finance departments at Verastem Oncology, SimpliVity Corp., PAREXEL, Inc. and Hologic Inc. Mr. Doyle earned a Bachelor of Science in finance from the University of Massachusetts.

Mr. Doyle added, “Cognition is fortunate to have a strong base of grant awards from the National Institutes of Health to support many of its studies. As a clinical-stage biotech, the company will need to execute on a financial plan that fosters value creation and generates opportunity in various market conditions. I am looking forward to working with Cognition’s leadership, finance team and board as the company evolves.”

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data and pre-clinical studies being predictive of the results of clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impact of the ongoing COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described in the “Risk Factors” section of our annual report filed with the Securities & Exchange Commission. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact Information:

Cognition Therapeutics, Inc.

Bill Borden (media)

Tiberend Strategic Advisors, Inc

Daniel Kontoh-Boateng (investors)

Tiberend Strategic Advisors, Inc.